ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
GSK plc ADRhedged
80.40
+1.34
1.69%
成交量:
1,867.00
成交额:
15.02万
市值:
80.41万
市盈率:
- -
高:
80.60
开:
80.59
低:
80.27
收:
79.06
52周最高:
85.03
52周最低:
48.14
股本:
1.00万
流通股本:
1.00万
量比:
1.39
换手率:
18.67%
股息:
1.15
股息率:
1.43%
净资产收益率:
--
总资产收益率:
--
市净率:
--
市盈率(LYR):
- -
数据加载中...
总览
公司
新闻资讯
公告
概念
没有相关数据
资金流向
资金流入:
资金流出:
实时
日
周
月
季度
年
新闻资讯
葛兰素史克(GSK.US)超长效单抗新药新适应症在中国获批上市
智通财经
·
昨天
三星生物制剂2.8亿美元收购葛兰素史克美国工厂
环球市场播报
·
04/01
葛兰素史克德莫奇单抗获批上市,系中国首款治疗嗜酸性表型重度哮喘的超长效生物制剂
北京商报
·
03/31
曾长期缺货,葛兰素史克乙肝疫苗安在时重返中国市场
红星资本局
·
03/26
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/GSKH"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":80.4,"timestamp":1775160000000,"preClose":79.0627,"halted":0,"volume":1867,"delay":0,"changeRate":0.016914423615687284,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"耶稣受难日休市","change":1.3373,"latestTime":"04-02 16:00:00 EDT","open":80.59,"high":80.6,"low":80.27,"amount":150159.3801,"amplitude":0.004174,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":79.0627,"nav":78.89975,"aum":789076.39975,"dividendRate":0.0143,"bidAskSpread":0,"volumeRatio":1.38748530172239,"impliedVol":0.1947,"impliedVolPercentile":0.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.38748530172239,"shares":10001,"dividePrice":1.1497,"high":80.6,"amplitude":0.004174,"preClose":79.0627,"low":80.27,"week52Low":48.14,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":80.4,"eps":0,"divideRate":0.0143,"volume":1867,"delay":0,"ttmEps":0,"open":80.59,"prevYearClose":68.2031,"prevWeekClose":76.4288,"prevMonthClose":78.32,"prevQuarterClose":78.32,"fiveDayClose":76.2059,"twentyDayClose":78.0301,"sixtyDayClose":70.4249},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624765321","title":"葛兰素史克(GSK.US)超长效单抗新药新适应症在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2624765321","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624765321?lang=zh_cn&edition=fundamental","pubTime":"2026-04-03 15:51","pubTimestamp":1775202696,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,4月3日,NMPA官网显示,葛兰素史克“德莫奇单抗”新适应症获批上市,用于治疗慢性鼻窦炎伴鼻息肉病。2025年12月,德莫奇单抗在美国迎来全球首批。2026年3月,德莫奇单抗首次登陆中国市场。本次是德莫奇单抗在国内获批的第 2 项适应症。GSK拥有实力雄厚、行业领先的呼吸产品管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"葛兰素史克(GSK.US)超长效单抗新药新适应症在中国获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","BK4588","LU1829250122.USD","GSK.UK","GSK","BK4585","BK4007","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624561681","title":"三星生物制剂2.8亿美元收购葛兰素史克美国工厂","url":"https://stock-news.laohu8.com/highlight/detail?id=2624561681","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624561681?lang=zh_cn&edition=fundamental","pubTime":"2026-04-01 13:12","pubTimestamp":1775020320,"startTime":"0","endTime":"0","summary":"三星集团旗下生物技术公司三星生物制剂周三表示,已斥资 2.8 亿美元收购了英国制药巨头葛兰素史克在美国的一家工厂。 三星生物制剂公司在一份新闻稿中表示,位于马里兰州罗克维尔的这家工厂拥有6万升原料药的生产能力,使该公司的总产能达到84.5万升。 三星生物制剂表示,计划进一步投资以扩大工厂产能并升级技术,从而巩固其加强全球供应链和改善关键药物可及性的长期承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-01/doc-inhsynau2671180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1829250122.USD","GSKH","BK4585","BK4532","BK4588","GSK.UK","BK4007","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623001503","title":"葛兰素史克德莫奇单抗获批上市,系中国首款治疗嗜酸性表型重度哮喘的超长效生物制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2623001503","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623001503?lang=zh_cn&edition=fundamental","pubTime":"2026-03-31 17:54","pubTimestamp":1774950879,"startTime":"0","endTime":"0","summary":"北京商报讯(记者丁宁)葛兰素史克近日宣布,中国国家药品监督管理局批准易适来(德莫奇单抗)用于成人和12岁及以上青少年重度嗜酸性粒细胞性哮喘的维持治疗。据了解,易适来获批用于重度哮喘的治疗是基于SWIFT-1和SWIFT-2两项Ⅲ期临床试验的研究数据。在这两项均联合标准治疗的研究中,相较于安慰剂组,德莫奇单抗每年给药两次,能持续减少哮喘急性发作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603313690543314.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690543314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","GSK.UK","GSK","GSKH","BK4588","BK4585","LU1829250122.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850002","title":"曾长期缺货,葛兰素史克乙肝疫苗安在时重返中国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850002","media":"红星资本局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850002?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 20:36","pubTimestamp":1774528560,"startTime":"0","endTime":"0","summary":"红星资本局3月26日消息,一款在2022年就被传出缺货的进口乙肝疫苗,宣布重返中国市场。3月25日,葛兰素史克(GSK)宣布与科园信海(北京)医疗用品贸易有限公司(简称“上药科园贸易”)就乙肝疫苗安在时(EngerixB,重组乙型肝炎疫苗(酿酒酵母))启动战略合作。GSK表示,2026年正值安在时全球上市40周年,此次重返中国市场是满足市场需求的有力举措。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685856696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0963586101.USD","BK4532","GSKH","LU1829250122.USD","GSK.UK","BK4007","BK4614","ASHS","ASHR","DRAG","BK4585","KWEB","BK4588","BK4504","CQQQ","GSK"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/GSKH\",params:#limit:6,delay:false,,,undefined,":[]}}